Ad Campaign

Lilly launched a new ad campaign, "Healthy Skepticism" against counterfeit and compounded drugs. What does Lilly say about counterfeit and compound drugs? Fake or counterfeit products are produced and marketed in ways that misrepresent their efficacy, provenance, or authenticity. Counterfeit (fake or falsified) medicines may be harmful to your health because while being passed off as authentic, may contain the wrong ingredients, contain too much, too little or no active ingredient at all or contain other harmful ingredients. Statement defined by U.S. FDA. Compounded drugs are those in which process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. Also Read: Based on Results From the Phase 3 BRUIN CLL-321 trial, Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union Context of Ad Campaign Two blockbuster weight loss drugs including Lilly's Zepbound were in U.S. FDA's drugs shortage list. During this period federal regulation allowed the sale of compound drugs to meet the requirement. However, Zepbound was removed from the U.S. FDA shortage list. Source: Eli Lilly and Company - Safety Last Modified:

Tag: Ad Campaign

“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs

Areas Covered

Discover More

Pfizer and Valneva Announce Strong Efficacy for Lyme Disease Vaccine Candidate

Novo Nordisk’s UBT251 Triple Agonist Achieves Landmark 2.16% HbA1c Reduction in Type 2 Diabetes Phase 2 Trial

Novartis Immunology Data at AAD 2026: Rhapsido and Cosentyx Results

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide